<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04152174</url>
  </required_header>
  <id_info>
    <org_study_id>PPI-2018-06-5</org_study_id>
    <nct_id>NCT04152174</nct_id>
  </id_info>
  <brief_title>Safety and Efficiency of Combined Extracorporeal Blood Purification in Neurosurgical ICU. Prospective RCT</brief_title>
  <acronym>NEUROCOMB</acronym>
  <official_title>Pilot Prospective Randomized Controlled Study of Safety and Efficiency of Combined Extracorporeal Blood Purification in Neurosurgical ICU in Comparison With the Continuous Renal Replacement Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Burdenko Neurosurgery Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Burdenko Neurosurgery Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the efficiency and safety of combined extracorporeal blood purification in patients
      with septic shock in Neurosurgical ICU in comparison with the efficiency and safety of the
      continuous renal replacement therapy (CRRT).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      According to studies and modern sepsis treatment guidelines, conventional CRRT has not proved
      effective in the septic shock treatment.

      Effectiveness of other extracoporeal blood purification methods, such as hemoadsorption or
      combined blood purification (hemoadsorption combined with CRRT) is widely pointed out in
      current publications: contemporary studies in general ICU patients demonstrated that the use
      of hemoadsorption or combined extracorporeal blood purification methods is effective for
      septic shock patients treatment.

      It has been proven that cytokines discharged into the systemic blood flow are the key
      pathophysiological mechanism of septic shock. Hemoadsorption allows for significantly more
      effective removal of different inflammatory mediators than the traditional methods of CRRT.
      The combined extracorporeal blood purification method demonstrated similar efficacy in
      general ICU patients.

      The aim of this study is to assess the efficiency and safety of combined extracorporeal blood
      purification in with septic shock in neurosurgical ICU in comparison with the efficiency and
      safety of the continuous renal replacement therapy (CRRT) with AN69 membrane.

      Study novelty: We have not encountered published studies evaluating the efficiency of
      combined extracorporeal blood purification methods in neurosurgical patients with septic
      shock. Furthermore, currently there is not enough data to compare combined extracorporeal
      blood purification with CRRT for septic shock treatment. The planned study is the first to
      investigate the safety and efficiency of combined extracorporeal blood purification in
      patients with septic shock in neurosurgical ICU.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 10, 2018</start_date>
  <completion_date type="Anticipated">May 10, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 10, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vasopressor dose reduction</measure>
    <time_frame>6, 12, 24, 48 and 72 hours after the randomization time</time_frame>
    <description>Vasopressor dose reduction value</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time on vasopressor support</measure>
    <time_frame>Up to a month after the randomization date</time_frame>
    <description>Time on vasopressor support</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Interleukins concentration reduction</measure>
    <time_frame>6, 12, 24 and 48 hours after the randomization time</time_frame>
    <description>Interleukins (IL-1β, IL-6, IL-8, IL-10) concentration reduction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor necrosis factor-α concentration reduction</measure>
    <time_frame>6, 12, 24 and 48 hours after the randomization time</time_frame>
    <description>Tumor necrosis factor-α concentration reduction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SOFA score reduction</measure>
    <time_frame>24, 48 and 72 hours after the randomization time</time_frame>
    <description>SOFA score reduction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total bilirubin concentration reduction</measure>
    <time_frame>6, 12, 24 and 48 hours after the randomization time</time_frame>
    <description>Total bilirubin concentration reduction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C - reactive protein level reduction</measure>
    <time_frame>24, 48 and 72 hours after the randomization time</time_frame>
    <description>C - reactive protein level reduction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procalcitonin concentration reduction</measure>
    <time_frame>6, 12, 24, 48 and 72 hours after the randomization time</time_frame>
    <description>Procalcitonin concentration reduction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PiCCO-derived parameters normalization</measure>
    <time_frame>6, 12, 24, 48 and 72 hours after the randomization time</time_frame>
    <description>Any PiCCO-derived parameter normalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arteriovenous pCO2 gap reduction</measure>
    <time_frame>6, 12, 24, 48 and 72 hours after the randomization time</time_frame>
    <description>Arteriovenous pCO2 gap reduction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial blood lactate level reduction</measure>
    <time_frame>6, 12, 24, 48 and 72 hours after the randomization time</time_frame>
    <description>Arterial blood lactate level reduction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU length of stay</measure>
    <time_frame>up to 3 months after the randomization date</time_frame>
    <description>ICU length of stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital stay time</measure>
    <time_frame>up to 3 months after the randomization date</time_frame>
    <description>Hospital stay time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical ventilation time</measure>
    <time_frame>up to 3 months after the randomization date</time_frame>
    <description>Mechanical ventilation time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Continuous renal replacement therapy time</measure>
    <time_frame>up to 3 months after the randomization date</time_frame>
    <description>Continuous renal replacement therapy time</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Intracranial hemorrhagic complication</measure>
    <time_frame>in 48 hours after the randomization time</time_frame>
    <description>Presence of any intracranial hemorrhagic complications</description>
  </other_outcome>
  <other_outcome>
    <measure>Extracranial hemorrhagic complication</measure>
    <time_frame>in 48 hours after the randomization time</time_frame>
    <description>Presence of extracranial hemorrhagic complications</description>
  </other_outcome>
  <other_outcome>
    <measure>Death in 28-days after CRRT inititiation</measure>
    <time_frame>28-days after the randomization date</time_frame>
    <description>28-days mortality in the observed sample group</description>
  </other_outcome>
  <other_outcome>
    <measure>In-hospital death</measure>
    <time_frame>in 3 months after the randomization date</time_frame>
    <description>Hospital mortality in the observed sample group</description>
  </other_outcome>
  <other_outcome>
    <measure>Albumin blood level reduction</measure>
    <time_frame>24 and 48 hours after the randomization time</time_frame>
    <description>Albumin blood level reduction of more than 10%</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>Combined extracorporeal blood purification</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CRRT with CVVHDF mode plus treatment with CytSorb adsorber</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CRRT with CVVHDF mode</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Combined extracorporeal blood purification</intervention_name>
    <description>Patients receive combined extracorporeal blood purification: CRRT in CVVHDF mode with AN 69 ST set (Baxter) and hemoadsorption with Cytosorbents Corp. CytoSorb adsorber.</description>
    <arm_group_label>Combined extracorporeal blood purification</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CRRT</intervention_name>
    <description>Patients receive CRRT in CVVHDF mode with AN 69 ST set (Baxter)</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of septic shock according to SEPSIS 3 definition

          -  Glasgow Coma Scale of 4 and more on admission

          -  invasive hemodynamics monitoring

          -  norepinephrine &gt; 0,1 µg/kg/min or use of 2 vasopressors

        Exclusion Criteria:

          -  patients, who undergo neurosurgical interventions in the operation theatre during the
             study

          -  age &lt;18 years

          -  &gt;24 hours after diagnosis of septic shock
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aleksandr Burov</last_name>
    <role>Study Chair</role>
    <affiliation>N. N. Burdenko National Medical Research Center of Neurosurgery</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aleksandr Burov</last_name>
    <phone>+79854215478</phone>
    <email>Aleksander.bour@mail.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gleb Danilov, Phd</last_name>
    <email>gdanilov@nsi.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Federal State Autonomous Institution &quot;N .N. Burdenko National Medical Research Center of Neurosurgery&quot; of the Ministry of Healthcare of the Russian Federation</name>
      <address>
        <city>Moscow</city>
        <zip>125047</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aleksandr Burov</last_name>
      <phone>+79854215478</phone>
      <email>Aleksander.bour@mail.ru</email>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>September 21, 2019</study_first_submitted>
  <study_first_submitted_qc>November 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2019</study_first_posted>
  <last_update_submitted>November 1, 2019</last_update_submitted>
  <last_update_submitted_qc>November 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>blood purification</keyword>
  <keyword>CRRT</keyword>
  <keyword>septic shock</keyword>
  <keyword>neurosurgery</keyword>
  <keyword>cytokine removal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

